Taisho Pharmaceutical Co

Mar 19, 2024 | academic.oup.com | Taisho Pharmaceutical Co

Acromegaly and gigantism are disorders caused by hypersecretion of growth hormone (GH), usually from pituitary adenomas. Although somatostatin analogues (SSA), dopamine agonists and GH receptor antagonist are important therapeutic agents, all of these have issues with their effectiveness, safety, and/or convenience of use. To overcome these, we developed a GH-specific potent neutralizing mouse monoclonal antibody (mAb) named 13H02.

Nov 1, 2023 | accp1.onlinelibrary.wiley.com | Tsutomu Takeuchi |Taisho Pharmaceutical Co |Ltd. Osaka Japan |Yukihiro Chino

Ozoralizumab is a bispecific NANOBODY® compound that binds tumor necrosis factor alpha (TNFα) and human serum albumin (HSA). Ozoralizumab inhibits the TNFα physiological activity while maintaining long-term plasma retention owing to its HSA-binding ability. A population pharmacokinetic (PK) model was developed using data from 494 Japanese patients with rheumatoid arthritis (RA) in phase II/III and phase III trials to assess the effects of potential PK covariates.

Apr 14, 2023 | arthritis-research.biomedcentral.com | Taisho Pharmaceutical Co

ReferencesWolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: work disability: a prospective 18 year study of 823 patients. J Rheumatol. 1998;25(11):2108–17. CAS  PubMed  Google Scholar  Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26.